Ozempic Subsidies Cut in Novo Nordisk’s Home Country of Denmark
- Some Ozempic reimbursement kept after Novo agrees to price cut
- Medicines Agency aims to bring GLP-1 users on to cheaper drugs
This article is for subscribers only.
Subsidies for Ozempic will be restricted in Novo Nordisk A/S’s home country of Denmark due to rising public spending on the blockbuster diabetes medicine, which is increasingly being used as a weight-loss treatment.
The Danish Medicines Agency will keep some subsidies in place for GLP-1 analogues used to treat type 2 diabetes after Novo agreed to lower prices. But the authority will tighten current rules and only reimburse patients who can’t be treated with cheaper alternatives, according to a statement on Wednesday.